Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study

Zhe Chen1†, Aihua Liu1†, Yongjing Cheng1*, Xutao Wang2, Xiaomao Xu3, Jia Huang1, Yuqing Ma1, Ming Gao1 and Cibo Huang1

Abstract

Background: Since the COVID-19 pandemic, several therapeutic agents have been used in COVID-19 management. However, the results were controversial. Here, we aimed to evaluate the efficacy and safety of hydroxychloroquine (HCQ)/chloroquine (CQ) in COVID-19.

Methods: We retrospectively reviewed the medical charts of patients with COVID-19 admitted to an inpatient ward in Wuhan from 2020/Feb/08 to 2020/Mar/05. Patients with HCQ/CQ and age, gender, disease severity matched ones without HCQ/CQ were selected at a 1:2 ratio. The clinical, laboratory and imaging findings were compared between these two groups. The multivariate linear regression analysis was performed to identify the factors that might influence patients' virus shedding periods (VSPs).

Results: A total of 14 patients with HCQ/CQ and 21 matched ones were analyzed. The HCQ/CQ treatment lasted for an average of 10.36 ± 3.12 days. The mean VSPs were longer in the HCQ/CQ treatment group (26.57 ± 10.35 days vs. 19.10 ± 7.80 days, \(P = 0.020\)). There were 3 patients deceased during inpatient period, two patients were with HCQ/CQ treatment (\(P = 0.551\)). In the multivariate linear regression analysis, disease durations at admission (\(t = 3.643, P = 0.001\)) and HCQ/CQ treatment (\(t = 2.637, P = 0.013\)) were independent parameters for patients' VSPs. One patient with CQ had recurrent first-degree atrioventricular block (AVB) and obvious QTc elongation, another one complained about dizziness and blurred vision which disappeared after CQ discontinuation. One patient with HCQ had transient AVB.

Conclusions: In summary, we identify that the HCQ/CQ administration is not related to less mortality cases at later phase of COVID-19. More studies are needed to explore whether HCQ/CQ treatment would lead to SARS-Cov-2 RNA clearance delay or not.

Keywords: Hydroxychloroquine, Chloroquine, Virus shedding periods, COVID-19

Background

Since December 2019, the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection has swept over the whole world in a few months. By May 5, 2020, more than 3.5 million cases have been confirmed and the death toll raises to over 250 thousand all around the world. The SARS-Cov-2 infection results in the coronavirus disease-2019 (COVID-19), which is composed of a spectrum of clinical manifestations including pneumonia, heart/kidney/liver injury, and coagulopathy, etc. [1, 2].

Due to lacking of specific anti-virus drugs, the management of COVID-19 is still challenging. The results of two randomized controlled clinical trials of the promising
anti-virus agents, i.e. Lopinavir/Ritonavir and Remdesivir, showed that these drugs were not that effective as we had expected in Chinese patients with COVID-19 [3, 4]. Because of the dramatic elevation of several inflammatory factors, such as interferon-γ-induced protein 10, monocyte chemotactic protein-3, interleukin-13, et al., overreactive immunopathological mechanisms were surmised to be responsible for multiple organ damage in COVID-19 [5]. Some researchers hypothesized that patients with COVID-19 might benefit from some anti-rheumatic drugs, such as hydroxychloroquine (HCQ)/chloroquine (CQ) and tocilizumab (TCZ), for their dual effects on immune regulation and suppression [6].

CQ is a traditional anti-malaria drug. As a derivate of CQ, HCQ is less toxic to retina and heart and is the background treatment in systemic lupus erythematosus (SLE) [7]. Yu and colleagues reported that HCQ treatment could reduce serum interleukin-6 (IL-6) levels in COVID-19 patients [8]. Except for the anti-inflammatory activity, HCQ/CQ has potential anti-virus effects [9, 10]. Liu et al. reported that both HCQ and CQ could inhibit SARS-Cov-2 replication and prevent the virus from entering into cells in vitro [11]. HCQ/CQ was recommended as an option in the COVID-19 management guideline in China [12, 13]. Furthermore, both the US Food and Drug Administration and the Indian Council for Medical Research had permitted the empiric use of HCQ in COVID-19 patients [14, 15]. With the surging demands for HCQ in COVID-19, some patients under long-term HCQ treatment for autoimmune disease, such as SLE, were threatened by HCQ shortage. Therefore, some rheumatologists campaigned for using HCQ rationally in COVID-19 in which the data and evidence were limited and inconclusive [16]. Unfortunately, the efficacy of HCQ/CQ in COVID-19 remained equivocal by far.

At the very beginning of the outbreak of COVID-19, a multidisciplinary medical team from Beijing Hospital took in charge of an independent inpatient ward to manage the COVID-19 patients in the Sino-French New City Branch of Tongji Hospital in Wuhan, China. Some patients took HCQ/CQ during their inpatient period. We performed the following retrospective analysis to evaluate the potential efficacy and safety of HCQ/CQ in COVID-19.

**Methods**

**Patients**

Medical charts of patients admitted to one inpatient ward in Wuhan from February 08, 2020 to March 05, 2020 were reviewed. Due to the potential while uncertain efficacy of TCZ in COVID-19, patients receiving TCZ treatment were excluded from the study. Patients with HCQ/CQ treatment and age, gender, disease severity matched ones without HCQ/CQ treatment were analyzed. The matching process was performed with the SPSS software (version 26.0) and the propensity-score (PS) matching package at a 1:2 ratio. The Caliper value was 0.2.

**Methods**

This was a retrospective cohort study. The demographic data, clinical manifestations, comorbidities, laboratory findings and image involvement patterns assessed by computed tomography (CT) were carefully and thoroughly collected from medical charts.

The disease severity was defined as mild, general, severe and critically severe according to the Chinese management guideline for COVID-19 (Additional file 1) [12]. The CURB-65 severity score was calculated according to the standard definition [17]. The estimated glomerular filtration rate (eGFR) was calculated via the CKD-EPI equation [18]. The concurrent respiratory pathogen infections, including type A influenza, type B influenza, mycoplasma pneumoniae, chlamydia pneumoniae, respiratory syncytial virus, adenovirus, parainfluenza virus and legionella pneumonia infections, were confirmed by the presence of pathogen specific immunoglobulin M with the enzyme-linked immunosorbent assay.

The nasopharyngeal swabs were sampled based on physicians’ judgement on clinical purposes. And the ribonucleic acids (RNAs) of SARS-Cov-2 were examined with the polymerase chain reaction (PCR) method [19]. The virus shedding periods (VSPs) were defined from symptoms onset to the first day of the consecutive negative PCR results before discharge (Additional file 1). Drugs taken by the patients for COVID-19 management purposes before admission were recorded and analyzed as well. Receiving corticosteroids (GCs) treatment was defined as exposure to systemic GCs. The dosage of GCs was calculated by methylprednisolone (MP) (prednisone: methylprednisolone = 1.25:1). The complains and symptoms after HCQ/CQ initiation were carefully recorded.

**Statistical analysis**

Statistics analyses were conducted with the SPSS software (version 26.0). Numerical data was expressed as mean ± standard deviation (SD) or quartiles (Q1: first quartile; Q2: second quartile; Q3: third quartile), while categorical data was expressed as numbers and percentages. Numerical data was compared with the independent sample t-test. Categorical data was compared with the Chi-square or the Fisher’s exact test, as appropriate. The multivariate linear regression analysis was performed to identify the factors that might influence patients’ VSPs. Virus shedding periods were the dependent variable. Continuous or dichotomous parameters, such as
disease duration at admission, with or without HCQ/CQ treatment, dosage of GCs et al. selected according to clinical judgment, were analyzed as probable predict variables with the stepwise method in the multivariate linear regression analysis (Additional file 1: Table S1). Laboratory results which were statistically different between patients with and without HCQ/CQ were selected as probable predict variables as well. MP dosage in patients without GCs was recorded as zero. All probabilities were 2-sided, and P values < 0.05 were considered to be statistically significant.

Results

From February 8, 2020 to March 5, 2020, a total of 63 COVID-19 patients were admitted to our ward. All the patients were confirmed with SARS-Cov-2 infection via PCR. Except for 5 patients who received TCZ treatment, 58 patients were treated by non-biological drugs. Among the 58 patients, 11 and 3 patients received HCQ and CQ treatment, respectively. After age, gender and disease severity matching, 21 patients without HCQ/CQ treatment were selected as controls and were further analyzed (Fig. 1).

For the 35 patients, the average age was 62.20±11.88 years old with a male predominance. The span from symptoms onset to admission were 13.00±7.24 days. Although common at disease onset (77.14%), fever was observed in only 20% of patients at admission. Twenty-six patients (74.28%) had at least a comorbidity, most of which was hypertension. Twenty-one out of the 35 patients suffered from multiple pathogen infections in addition to SARS-Cov-2. And influenza was the most common concomitant infectious disease (57.14%) (Table 1). Procalcitonin elevation was recorded in 9 patients. Serum ferritin and IL-6 levels were elevated in 34 and 17 patients, respectively. Serum IL-1β, IL-2R, IL-8, IL-10 and tumor necrosis factor-α (TNF-α) levels were tested in 14 patients. As a result, serum IL-1β, IL-2R, IL-8, IL-10 and TNF-α elevation were recorded in 1, 8, 2, 0 and 6 patients, respectively.

Twenty-two patients took anti-influenza drugs, i.e., oseltamivir or arbidol or both. Most patients (94.28%) received traditional Chinese medicine (TCM) treatment.

![Fig. 1](image-url) The flow diagram of patient selection in the present study. COVID-19 corona virus disease-2019, TCZ tocilizumab, HCQ hydroxychloroquine, CQ chloroquine
|                                | Total (n = 35) | With HCQ/CQ (n = 14) | Without HCQ/CQ (n = 21) | P value |
|--------------------------------|----------------|----------------------|-------------------------|---------|
| **Age**                        | 62.20±11.88    | 61.00±13.00          | 63.00±11.33             | 0.633   |
| **Sex**                        |                |                      |                         |         |
| Male                           | 23             | 10                   | 13                      | 0.721   |
| **Disease duration (days)**    | 13.00±7.24     | 13.00±7.14           | 13.00±7.49              | 1.000   |
| **Clinical manifestation at beginning** |                |                      |                         |         |
| Fever                          | 27             | 10                   | 17                      | 0.685   |
| Fatigue                        | 25             | 11                   | 14                      | 0.704   |
| Cough                          | 26             | 12                   | 14                      | 0.262   |
| Diarrhea                       | 8              | 3                    | 5                       | 1.000   |
| Myalgia/arthritis              | 10             | 7                    | 3                       | 0.053   |
| Fever at admission             | 7              | 2                    | 5                       | 0.676   |
| **Comorbidities**              |                |                      |                         |         |
| Hypertension                   | 13             | 7                    | 6                       | 0.199   |
| Diabetes mellites              | 5              | 2                    | 3                       | 1.000   |
| Carcinoma                      | 5              | 3                    | 2                       | 0.369   |
| Stroke                         | 1              | 1                    | 0                       | 0.400   |
| Coronary artery disease        | 2              | 1                    | 1                       | 1.000   |
| Lung disease                   | 6              | 1                    | 5                       | 0.366   |
| HBV infection                  | 7              | 3                    | 4                       | 1.000   |
| **Disease severity status**    |                |                      |                         |         |
| General                        | 19             | 7                    | 12                      | 0.678   |
| Severe/critical                | 16             | 7                    | 9                       |         |
| CURB-65 score                  |                |                      |                         |         |
| 0                              | 15             | 6                    | 9                       | 1.000   |
| 1–5                            | 20             | 8                    | 12                      |         |
| **Laboratory results**         |                |                      |                         |         |
| WBC (× 10⁹/L)                  | 6.13±2.45      | 6.27±2.96            | 6.05±2.12               | 0.801   |
| Neu (× 10⁹/L)                  | 4.33±2.38      | 4.68±2.88            | 4.10±2.01               | 0.490   |
| Lym (× 10⁹/L)                  | 1.08±0.52      | 1.05±0.56            | 1.09±0.50               | 0.828   |
| Neu/Lym                        | 5.27±4.31      | 6.16±5.13            | 4.69±3.67               | 0.329   |
| Hb (g/L)                       | 123.17±18.43   | 126.14±19.22         | 121.19±18.08            | 0.444   |
| PLT (× 10⁹/L)                  | 266.37±111.96  | 283.86±110.58        | 254.71±114.04           | 0.459   |
| ALT (U/L)                      | 33.14±28.69    | 27.00±21.31          | 37.24±32.56             | 0.308   |
| AST (U/L)                      | 32.11±20.96    | 27.00±13.72          | 35.52±24.37             | 0.244   |
| Alb (g/L)                      | 33.26±5.60     | 31.94±6.51           | 34.14±4.87              | 0.260   |
| LDH (U/L)                      | 282.69±126.59  | 310.00±130.40        | 264.48±123.78           | 0.304   |
| eGFR (mL/min/1.73 m²)          | 89.33±15.88    | 86.17±12.15          | 91.43±17.92             | 0.345   |
| > 90 mL/min/1.73 m²            | 20             | 7                    | 13                      | 0.486   |
| ≤ 90 mL/min/1.73 m²            | 15             | 7                    | 8                       |         |
| Fibrinogen (g/L)               | 5.17±1.59      | 5.82±1.19            | 4.74±1.66               | 0.045   |
| D-Dimer (ug/mL FEU)            | 3.63±5.42      | 4.30±6.65            | 3.18±4.54               | 0.556   |
| > 1.0 ug/mL FEU                | 21             | 8                    | 13                      | 0.778   |
| ≤ 1.0 ug/mL FEU                | 14             | 6                    | 8                       |         |
| NT-pro-BNP (ug/mL)             | 253.20±346.51  | 318.29±520.19        | 209.81±152.60           | 0.372   |
| cTnI (pg/mL)                   | 9.11±9.51      | 8.43±9.38            | 9.56±9.79               | 0.736   |
| ESR (mm/h) / (r)               | 47.75±26.74 (32) | 58.62±19.90 (13)    | 40.32±28.70 (19)        | 0.056   |
| hsCRP (mg/L)                   | 33.89±38.61    | 31.47±24.06          | 35.50±46.39             | 0.767   |
| Procalcitonin (ng/mL)          | 0.17±0.46      | 0.10±0.08            | 0.21±0.60               | 0.507   |
| ≥ 0.1 ng/mL                    | 9              | 5                    | 4                       | 0.432   |
| < 0.1 ng/mL                    | 26             | 9                    | 17                      |         |
And the total types of anti-virus agents were similar between these two treatment groups (Table 2). Antibiotics were concomitantly administrated with HCQ/CQ in 17 patients. And moxifloxacin was the most commonly used antibiotic (13/17). HCQ/CQ was not administrated in combination with azithromycin in our patients. GCs were administrated in 12 (34.28%) patients. There were more patients taking GCs in the HCQ/CQ treatment group (57.14% vs. 19.05%, \( P = 0.031 \)) (Table 2). The detailed information of GCs was available in 11 patients. Patients took GCs at a median of 14 days after symptoms onset (Q1: 12 days, Q3: 19 days). The GCs treatment lasted for a median of 6 days (Q1: 4 days, Q3: 7 days).

### Table 1 (continued)

|                           | Total (n = 35) | With HCQ/CQ (n = 14) | Without HCQ/CQ (n = 21) | \( P \) value |
|---------------------------|---------------|----------------------|------------------------|---------------|
| Ferritin (ug/L) (n)       | 819.36 ± 628.02 (31) | 689.45 ± 494.53 (13) | 913.18 ± 707.92 (18) | 0.336         |
| IL-6 (ug/mL) (n)          | 14.49 ± 15.62 (31) | 13.28 ± 9.27 (13)    | 15.37 ± 19.19 (18)   | 0.721         |
| Other respiratory pathogen infection\(^c\) | 21             | 10                   | 11                     | 0.260         |

### Imaging findings

- GGO: 30
- Consolidation: 19
- Bilateral pulmonary infiltration: 34
- Interstitial changes: 17
- Hydrothorax: 7

### Table 2

| Treatment                        | Total (n = 35) | With HCQ/CQ (n = 14) | Without HCQ/CQ (n = 21) | \( P \) value |
|----------------------------------|---------------|----------------------|------------------------|---------------|
| **Antivirus agents**             |               |                      |                        |               |
| Ribavirin                        | 9             | 4                    | 5                      | 1.000         |
| Lopinavir/Ritonavir              | 4             | 1                    | 3                      | 0.635         |
| Oxelamivir                       | 18            | 8                    | 10                     | 0.581         |
| Arbidol                          | 10            | 6                    | 4                      | 0.151         |
| TCM                              | 33            | 14                   | 19                     | 0.506         |
| Types of antivirus agents        | 2.11 ± 0.93   | 2.36 ± 0.75          | 1.95 ± 1.02            | 0.213         |
| Corticosteroids                  | 12            | 8                    | 4                      | 0.031         |
| IVIG                             | 9             | 4                    | 5                      | 1.000         |
| Antibiotics                      | 22            | 10                   | 12                     | 0.392         |
| Anticoagulant                    | 8             | 3                    | 5                      | 1.000         |
| Virus shedding period (days)     | 22.09 ± 9.51  | 26.57 ± 10.35        | 19.10 ± 7.80           | 0.020         |
| Swab testing times               | 3.81 ± 2.04   | 5.15 ± 2.38          | 2.89 ± 1.10            | 0.001         |
| Consecutive swab testing negative times before discharging | 3.03 ± 1.23 | 3.23 ± 1.42 | 2.89 ± 1.10 | 0.457 |
| Swab testing interval (days)     | 6.10 ± 1.63   | 5.77 ± 1.36          | 6.34 ± 1.80            | 0.346         |
| **Outcomings**                   |               |                      |                        |               |
| Discharged                       | 32            | 12                   | 20                     | 0.551         |
| Deceased                         | 3             | 2                    | 1                      |               |

### Notes

- HBV: Hepatitis B virus
- WBC: White blood cell
- Neu: Neutrophil
- Lym: Lymphocyte
- Hb: Hemoglobin
- PLT: Platelet
- ALT: Alanine transaminase
- AST: Oxaloacetic transaminase
- LDH: Lactate dehydrogenase
- eGFR: Estimated glomerular filtration rate
- NT-pro-BNP: N-terminal pro-Brain Natriuretic Peptide
- cTnI: Cardiac troponin I
- ESR: Erythrocyte sedimentation rate
- hsCRP: High sensitivity C reactive protein
- IL-6: Interleukin-6
- GGO: Ground glass opacity
- HCQ: Hydroxychloroquine
- CQ: Chloroquine

\( ^a \) Including carcinoma in the stomach (n = 2), urinary bladder (n = 1), bone (n = 1) and breast (n = 1)

\( ^b \) Lung disease refers to chronic obstructive lung disease (n = 3), emphysema (n = 2), bronchiectasis (n = 1), lung fibrosis (n = 1) and bullae (n = 1)

\( ^c \) Other concurrent respiratory pathogen infection with a specific serum immunoglobulin M positive confirmed by the enzyme-linked immunosorbent assay includes type A influenza (n = 18), type B influenza (n = 2), mycoplasma pneumoniae (n = 2) and chlamydia pneumoniae (n = 1)
And the median cumulated dosage of GCs was 280 mg (MP or equivalent, Q1: 160 mg, Q3: 480 mg).

The dosage of HCQ was either 200 mg (n = 5) or 400 mg (n = 6) twice a day. And the dosage of CQ was 500 mg (n = 3) twice a day (Fig. 2). The average disease duration before HCQ/CQ initiation was $21.00 \pm 5.98$ days (Q1: 16.50 days; Q2: 22.00 days; Q3: 26.25 days). The HCQ/CQ treatment lasted for an average of $10.36 \pm 3.12$ days (Q1: 10.75 days; Q2: 11.00 days; Q3: 12.00 days). Only 1 of the 14 patients received HCQ/CQ treatment after virus shedding. The SARS-CoV-2 RNA tests turned negative after an average of $7.31 \pm 6.05$ days (Q1: 3.00 days; Q2: 5.00 days; Q3: 9.50 days) since HCQ/CQ initiation in the rest 13 patients. The average VSPs were $22.09 \pm 9.51$ days, which was a little longer in the HCQ/CQ treatment group ($26.57 \pm 10.35$ days vs. $19.10 \pm 7.80$ days, $P = 0.020$). However, the average swab testing intervals didn’t differ between patients with and without HCQ/CQ treatment statistically ($5.77 \pm 1.36$ days vs. $6.34 \pm 1.80$ days, $P = 0.346$) (Table 2). For the patients whose VSPs were longer than 22 days, the

Fig. 2 The detailed clinical, treatment and outcome information of patients with HCQ/CQ treatment. HCQ hydroxychloroquine, CQ chloroquine, ESR erythrocyte sedimentation rate, hsCRP high sensitivity C reactive protein, IL-6 interleukin-6, TCM traditional Chinese Medicine, GCs glucocorticoids. Comorbidities refers to the types of comorbidities in one single patient. Disease severity was classified according to the Chinese management guideline for COVID-19. Disease duration (days) was calculated from symptom onset to inpatient department admission. GCs were summed as methylprednisolone or equivalent and the total dosages of GCs were recorded in the corresponding square, respectively. Patient No.10 had transient first-degree atrioventricular block (AVB). Patient No.12 complained about dizziness and blurred vision which disappeared after CQ discontinuation. Patient No.14 had recurrent AVB and obvious QTc elongation even after CQ withdrawn. The virus shedding period was defined from symptoms onset to the first day of the consecutive negative PCR results before discharge. The X was put in the square in which the data was not available.
differences of average VSPs in patients with and without HCQ/CQ treatment were not statistically different (31.75 ± 9.72 days/n = 8 vs. 28.67 ± 3.56 days/n = 6, P = 0.477). In the multivariate linear regression analysis, disease durations at admission (t = 3.643, P = 0.001) and HCQ/CQ treatment (t = 2.637, P = 0.013) were independent predict parameters for patients’ VSPs prediction (Additional file 1: Table S1). The linear regression formulation was listed as following. Here is an example. One male patient with COVID-19 was admitted to the hospital at the 5th day after symptom onset. He received HCQ therapy in the hospital. Therefore his expected virus shedding period was 21 (10.039 + 0.697 × 5 + 7.140 × 1 = 20.664) days. Meanwhile, neither GCs treatment (t = −0.313, P = 0.772) nor GCs dosage (t = −0.706, P = 0.766) was related to VSPs statistically. And after treatment, acute exudation lesions were largely absorbed in pulmonary CT (Fig. 3). There were 3 patients deceased during inpatient period in our study, and two patients were with HCQ/CQ treatment (P = 0.551). Two patients died from multiple organ failure. And the other patient died suddenly. Their relatives refused of autopsy. Thus, the exact reasons for their death were unknown.

Virus shedding period (days) = 10.039 + 0.697 × disease durations at admission + 7.140 × with or without HCQ/CQ treatment (0, if without HCQ/CQ treatment; 1, if with HCQ/CQ treatment).

Electrocardiographs (ECGs) were conducted at least once in 12 out of the 14 patients (9 patients with HCQ treatment, and 3 patients with CQ treatment). First-degree atrioventricular block (AVB) was recorded in 2 patients. One patient received HCQ and the other received CQ. No second or third AVB was noticed. First-degree AVB disappeared after HCQ discontinuation. However, the first-degree AVB disappeared after CQ.

**Fig. 3** The computed tomography findings of one patient (No. 6) before (week 0) and 1, 2, 3 weeks after HCQ administration, respectively. After the comprehensive treatment together with HCQ, the ground-glass opacity lesions were largely absorbed, while some of the fibrosis stripe lesions were left.
Discussion

The conventional anti-malaria drug HCQ/CQ was regarded as a promising agent for its dual effects on inflammation modulation and virus inhibition since the beginning of the pandemic [12, 14, 15]. During the past decades, several researchers had confirmed the anti-virus effects of HCQ/CQ in vitro and in vivo [7, 9, 10]. HCQ/CQ could prevent the coronavirus from entering the host cells by interfering with endosomal acidification which is essential for membrane fusion. However, coronavirus could invade the host cells via alternative non-endosomal pathway which is not blocked by HCQ/CQ [20]. CQ could also interfere with virus post translation modification by pondus hydrogenii (PH) modulation [21]. At the meantime, HCQ/CQ could act on host cells directly. HCQ/CQ could inhibit glycosylation of the cell membrane protein angiotensins converting enzyme-2, to which the SARS-Cov-2 is attached [22]. HCQ/CQ could downregulate the toll like receptor (TLR) on activated immune cells and block TLR signal transduction, and prohibit inflammatory factors secretion, such as IL-6 [8, 23]. By far, a few clinical studies have analyzed the efficacy of HCQ/CQ in COVID-19. Gautret and colleagues reported that most patients with COVID-19 were virologically cured 6 days after HCQ initiation, especially those who received HCQ in combination with azithromycin [24]. However, Gautret et al.’s study had a relatively small sample size and two selection bias. First, patients in the treatment and control group were not from the same medical center. Second, the virus loads in the HCQ treatment group were lower compared to those in the control group at inclusion. Lower virus loads indicated that the patients in the HCQ treatment group were at a later disease phase of SARS-Cov-2 infection and were more likely to have autolimiting disease course [25]. In a randomized clinical trial (RCT), Chen and colleagues reported that after HCQ treatment with a dosage of 400 mg/day for 5 days, the clinical and radiological improve rates were higher compared to those in patients without HCQ treatment (80.6% vs. 54.8%) [26]. In another randomized study with mildly to moderately ill COVID-19 patients, Tang et al. noticed that the SARS-Cov-2 negative conversion rates were similar in patients with and without HCQ treatment (85.4% vs. 81.3%) [27]. In a retrospective study, Mallat and colleagues reported that HCQ treatment was an independent factor for longer VSPs. The median time span from nasopharyngeal swab positivity to negativity were 17 days in the HCQ treatment group and 10 days in the control group, respectively (P=0.023). HCQ was administrated at an early stage of the disease course in Mallat’s study [28]. In our study, the number of mortality cases were not statistically different between patients with and without HCQ/CQ treatment. The result might be ascribed to several factors. Firstly, HCQ/CQ was administrated at a later phase of the disease course. In some patients, we used HCQ/CQ due to persistent SARS-Cov-2 RNA positivity for salvage treatment purposes. It is widely accepted that anti-virus should be taken as early as possible in influenza and corona virus infection [4, 29]. Secondly, the half-life of HCQ/CQ is as long as 40–60 days due to the large distribution volume in the blood. And it usually takes several weeks before HCQ/CQ reaching its maximal activity [30]. In COVID-19, HCQ/CQ treatment only lasted for an average of 10 days. Therefore, HCQ/CQ might be withdrawn before it worked. Thirdly, for ethic factors concern, several kinds of drugs, such as GCs, ribavirin, TCM et al., were administrated empirically and anecdotaly at the same time. These concomitantly taken drugs might have covered up the potential therapeutic effects of HCQ/CQ on COVID-19. Fourthly, due to the small sample size, the death rates were not statistically different in patients with and without HCQ/CQ treatment. Taken together, the efficacy of HCQ/CQ in COVID-19 management should be verified in large randomized controlled trials.

In the present study, the average VSPs were similar to those reported in the previous study [31]. After the multivariate linear regression analysis, we identified that disease durations at admission and HCQ/CQ treatment were independent parameters related to patients’ VSPs, indicating patients might have better prognosis if being well treated earlier. Furthermore, VSPs were not statistically different between patients with longer VSPs (VSPs > 22 days) in these two treatment groups. It was interesting that there were more patients who took GCs in the HCQ/CQ treatment group. However, after being adjusted by other confounders, neither GCs treatment nor GCs dosage was an independent parameter for VSPs prediction. Actually, the effect of GCs on COVID-19 remains controversial and disputable. In SARS and Middle East Respiratory Syndrome (MERS), GCs administration was related to delayed virus RNA clearance [32, 33]. However, in the SARS or MERS studies, patients were either critically ill [33] or took rather high GCs dosage [32]. On the other hand, patients with SARS or influenza might benefit from low-to-moderate GCs [34, 35]. In the discontinuation and reoccurred 10 days later. The QTc interval longer than 500 ms was recorded in the identical patient with CQ treatment. Another patient with CQ treatment complained about dizziness and blurred vision. And the symptoms disappeared after CQ being withdrawn. No patient complained about new symptoms during HCQ treatment.
present study, our patients took a low-to-moderate dose of GCs during a relative short period of time. As a result, we didn't find correlations between GCs treatment and prolonged VSPs. A team consist of front-line physicians from the Chinese Thoracic Society suggested that after careful benefits and harms evaluation, short term low-to-moderate dose of GCs could be prudently administrated in patients with COVID-19 [36].

One of the major concerns for HCQ/CQ treatment in COVID-19 is the side effect [37]. HCQ/CQ related retinopathy always occurs after months even years of HCQ/CQ administration [30]. Meanwhile, HCQ/CQ related arrhythmia might be lethal. And the risk is rising together with other arrhythmogenic drugs, such as azithromycin [30]. Borba et al. reported that high dose of CQ (600 mg twice daily) was related to prolonged QTc interval and should not be recommended in critically ill patients [38]. Lane and colleagues reported that HCQ monotherapy was safe in COVID-19. However, HCQ in addition to azithromycin might result in heart failure and cardiovascular mortality [39]. Tang et al. found that HCQ was safe in patients with COVID-19, the most common adverse effects were diarrhea and vomiting [27]. Similarly, HCQ was safe and tolerable in our patients. On the contrast, among the three patients with CQ treatment, one patient complained about dizziness and blurred vision and another patient had recurrent first-degree AVB and obvious QTc elongation.

The major limitation of the study was the relatively small sample size. There were only 14 patients received HCQ/CQ treatment due to the unsettled debate on the safety profile of HCQ/CQ in COVID-19. The sample size of the patients without HCQ/CQ was expected to be 28. However, after age, gender and disease severity matching, only 21 patients without HCQ/CQ treatment met the matching criteria and were finally selected. Secondly, some patients were treated with HCQ/CQ for persistent SARS-Cov-2 RNA positivity. These patients, per se, were refractory to treatment. Therefore, selection bias exists in our patients. Thirdly, due to the retrospective nature of the study, although we found out that HCQ/CQ treatment was related to longer VSPs, we couldn't tell whether HCQ/CQ prolonged SARS-Cov-2 RNA clearance or not.

Conclusions
In summary, we identify that the HCQ/CQ administration is not related to neither less mortality cases nor shorter VSPs at later phase of COVID-19. More studies are needed to explore whether HCQ/CQ treatment would lead to SARS-Cov-2 RNA clearance delay or not. And HCQ other than CQ is a safe and tolerable drug in COVID-19 patients.
References

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032.

2. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38. https://doi.org/10.1056/NEJMec2007575.

3. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99. https://doi.org/10.1056/NEJMoa2001282.

4. Wang YM, Zhang DY, Du GH, et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78. https://doi.org/10.1016/S0140-6736(20)31022-9.

5. Yang Y, Shen C, Li J, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020. https://doi.org/10.1016/j.jaci.2020.04.027.

6. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatment for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. https://doi.org/10.1001/jama.2020.6019.

7. Hughes G. Hydroxychloroquine: an update. Lupus. 2018;27(9):1402–3. https://doi.org/10.1177/096129361878040.

8. Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020. https://doi.org/10.1007/s11427-020-1732-2.

9. Aguirre-Cruz L, Torres KJ, Jung-Cook H, et al. Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. AIDS Res Hum Retrovir. 2010;26(3):339–42. https://doi.org/10.1089/ajd.2009.0129.

10. Ferrier RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;369:m1432. https://doi.org/10.1136/bmj.m1432.

11. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. https://doi.org/10.1038/s41421-020-0156-0.

12. National Health Commission of the People's Republic of China. Chinese expert consensus on comprehensive treatment of COVID-19 in Shanghai. Zhonghua Chuan Ran Bing Za Zhi. 2020;03.002. (in Chinese)

13. Group TSC-cte: Experts Consensus on comprehensive treatment of COVID-19 in Shanghai. Zhonghua Chuan Ran Bing Za Zhi. 2020;38(3):134–8. https://doi.org/10.3760/cma.j.issn.1000-6680.2020.03.002. (in Chinese)

14. Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ. 2020;369:m1333. https://doi.org/10.1136/bmj.m1333.

15. Indian Council for Medical Research. Recommendation for empiric use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection. https://icmr.nic.in/sites/default/files/upload_documents/HCQ_Recommendation_22March_final_MM_V2.pdf.

16. Yazdany J, Kim AHJ. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med. 2020. https://doi.org/10.7326/M20-1334.

17. Lim WS, van der Eerden MM, Laing R, et al. Defining community management guidelines for COVID-19 (version 6.0). http://www.nhc.gov.cn/czysjg/s7653p/202002/8334a83266d94d329d631f7d8aa8ec2/files/b218cf8f1b5c4639a2f27922b4f8b17.pdf. Accessed 19 Feb 2020.

18. Alia E, Grant-Kels JM. Does hydroxychloroquine combat COVID-19? A timeline of evidence. J Am Acad Dermatol. 2020;83(1):e33–4. https://doi.org/10.1016/j.jaad.2020.04.031.

19. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;2020.105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.

20. Kim AHJ, Sparks JA, Liew JW, et al. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med. 2020;172(12):819–21. https://doi.org/10.7326/M20-1223.

21. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020. https://doi.org/10.1101/2020.03.23.20040758.

22. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomized controlled trial. BMJ. 2020;369:m1849. https://doi.org/10.1136/bmj.m1849.

23. Mallat J, Fadi H, Balkis M, Mohamed MA, Mooty M, Malik A, Nusair A, Bonilla F. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: a retrospective study. medRxiv. 2020. https://doi.org/10.1101/2020.04.27.20081820.

24. Chen C, Yi Z, Huang J, Yin P, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Ju L, Zhang J, Wang X. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020. https://doi.org/10.1101/2020.03.17.20037432.

25. Schrezenmeier E, Donner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020. https://doi.org/10.1038/s41584-020-0372-x.

26. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa460.

27. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–9. https://doi.org/10.1016/S0924-9745(04)00272-2.

28. Mallouh Y, Moutsouhas Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):577–67. https://doi.org/10.1164/rccm.201706-1172OC.

29. Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1441–52. https://doi.org/10.1378/chest.129.6.1441.

30. Li Y, Yang SG, Gu L, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses. 2017;11(4):345–54. https://doi.org/10.10111/irv.12456.

31. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683–4. https://doi.org/10.1016/S0140-6736(20)30631-5.

32. Eljaaly K, Alireza KH, Alshehri S, et al. Hydroxychloroquine safety: a meta-analysis of randomized controlled trials. Travel Med Infect Dis. 2020;36:101812. https://doi.org/10.1016/j.tmaid.2020.101812.

33. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients...
hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857.

39. Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid widespread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv. 2020. https://doi.org/10.1101/2020.04.08.20054551.

**Publisher's Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.